Highland Global Allocation Fund has made headlines with a recent filing revealing that Raymond James & Associates now holds an 11% stake in the company. This change in ownership is significant as it highlights the ongoing interest in closed-end funds, a sector that continues to attract investment.
The filing, dated October 30, 2026, indicates that Raymond James beneficially owns 2,580,734.22 shares of Highland Global Allocation Fund. This stake was reported under a Schedule 13G/A, which is typically used by investors to disclose their ownership in a public company.
Background
Highland Global Allocation Fund, traded under the ticker HGLB on the NYSE, is an investment fund based in Dallas, Texas. The firm primarily focuses on investment strategies that involve a diversified portfolio, appealing to a wide range of investors. The recent filing is part of a series of disclosures, with the most recent prior to this being a NPORT-P/A on September 2, 2026.
What the Filing Says
The Schedule 13G/A filing reveals that Raymond James & Associates has no voting power but holds significant dispositive power over the shares it owns. Specifically, it states, "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business." This indicates that the shares were not acquired with the intent to influence control of the Highland Global Allocation Fund.
Impact
This disclosure may affect various stakeholders, including current investors and potential investors in Highland Global Allocation Fund. The presence of a major player like Raymond James could signal confidence in the fund's management and strategy. Other investment firms may look to reassess their positions in light of this new development, potentially leading to shifts in market dynamics.
What's Next
The filing does not say what happens next regarding this ownership change. However, it is likely that market participants will closely monitor any further developments or changes in share ownership as they could impact investment strategies across the sector.
Read Next
Freebird Partners Updates Stake in Ernexa Therapeutics
Jin Medical International Completes Key Equity Transfer
Vanguard Portfolio Management Discloses 8.64% Stake in JBG SMITH
Vanguard Portfolio Management Discloses 9.82% Stake in Newmark
Vanguard Portfolio Management amends stake in Inspire Medical
Vanguard Portfolio Management Discloses Major Stake in National Vision










